医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GENEVA

Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today that several of its scientific and business leaders will be participating at upcoming industry conferences and events, as follows:

BioJapan 2018
10 – 12 October 2018, Pacifico Yokohama, Yokohama, Japan
Selexis team members will attend and participate in business development and partnering activities. For more information, please visit: https://www.ics-expo.jp/biojapan/en/

BIO-Europe 24^th Annual International Partnering Conference
5 – 7 November 2018, Bella Center Copenhagen, Copenhagen, Denmark
Selexis team members will attend and participate in business development and partnering activities. For more information, please visit: https://ebdgroup.knect365.com/bioeurope/

JAACT 2018
5 – 8 November 2018, Tsukuba International Congress Center, Tsukuba, Japan
Selexis Chief Executive Officer Igor Fisch, PhD, will present, “Selexis Cell Line Development Platform, and Technologies for Assessment of Cell Line Integrity and Clonality,” followed by a joint Selexis/KBI presentation titled, “GENE to GMP in 9 Months – Accelerating the Development of Innovative Discoveries into Life-Changing Biological Medicines.” Additionally, Selexis will have representation at the JSR booth in the exhibit hall. For more information, please visit: https://www.aeplan.co.jp/jaact2018/index.html

10^th Annual PEGS Europe Protein & Antibody Engineering Summit
12 – 16 November 2018, Lisbon Congress Center, Lisbon, Portugal
Selexis Chief Executive Officer Igor Fisch, PhD, will present “Selexis’ SUREscan and SUREsignature: Technologies for Assessment of Cell Line Integrity and Clonality” on Wednesday, 14 November at 10:05 a.m. WET. Additionally, Selexis is a conference sponsor and exhibitor (booth #310). For more information, please visit: http://www.pegsummiteurope.com/

Antibody Engineering & Therapeutics
9 – 13 December 2018, Manchester Grand Hyatt San Diego, San Diego, CA
Selexis team members will attend the conference. For more information, please visit: https://lifesciences.knect365.com/antibody-engineering-therapeutics/

About Selexis SA

Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 100 drug products in clinical development and the manufacture of three commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. In June 2017, Selexis became part of the JSR Life Sciences group. JSR’s CDMO service offering leverages the full capabilities of Selexis’ proprietary SUREtechnology Platform™ to offer an end-to-end solution to industry. More information is available at www.selexis.com.

FOR MORE INFORMATION

- Web www.selexis.com
- LinkedIn www.linkedin.com/company/selexis-sa
- Twitter www.twitter.com/SelexisSA
- Facebook www.facebook.com/SelexisSA

View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005087/en/